The genetic revolution ushered in comprehensive understanding of genes; however, proteins are the major gene products. As the effectors of biological products, proteins warrant increased study and attention and thus, a proteomic evolution has begun.

Proteins, Protein Isoforms and Protein PTMs

Proteins are the gene products and thus their effectors [1-6]. Proteins can be part of two or more different biological processes due to two main intrinsic properties: protein-protein interactions (PPIs) and PTMs of proteins [1,2,7-10]. Being part of a protein complex with inhibitory properties (towards a particular biological process, e.g. cell motility) makes that protein an inhibitor of that biological process [5,6,11-16]. However, being part of a protein complex with activatory/stimulatory properties makes that protein an activator [7,13,17-20]. Therefore, depending on its interaction partners, the same protein can have dual or multiple functions [5,7,8,11,13,15,20].

Another intrinsic property that gives proteins dual and sometimes multiple function are PTMs [5-7,10,14,16,21]. There are many protein PTMs; among the most common are phosphorylation, glycosylation, acetylation, truncation or formation of disulfide bridges [1,5,7,20-25]. There are also intracellular specific protein PTMs (e.g. phosphorylation or acetylation) and extracellular protein PTMs (e.g. glycosylation, disulfide bridges, etc) [10,14, 17,23,26-29]. These protein PTMs are involved in a large variety of processes such as protein stability, enzymatic activity, signal transduction pathways, cytoskeletal remodeling, gene regulation or cell motility. Understanding the function of these protein PTMs can help in understanding physiological and pathological processes, which in turn can help us in understanding where, when and why one should take action to modify a physiological process (e.g. to create a virus/bacteria/pest/parasite-resistant transgenic plant), to use a physiological process (e.g. to produce a recombinant antibody) or to prevent, monitor, or even treat a pathological process (e.g. disease or disorders) [18,24,30-33]. Therefore, identification of these PPIs, protein PTMs, their location within the protein, as well as their status (e.g. covalent or non-covalent interactions, stable or transient interactions, etc) would provide valuable information about the status and function of that protein [18,24,30-33].

PTM Proteomics

Proteomics is the study of proteins, protein PTMs, PPIs of the cells, tissues, organs or organisms (or bodily fluids) at a particular stage or time-point (physiological or pathological, or during development) [1,2,7,17,34-36]. Proteomics is performed at both qualitative (protein and protein PTMs identification and characterization) and quantitative (protein and protein PTMs quantitation) [1,2,7,17,34-36].

Identification of common protein PTMs is more or less straightforward and it is usually performed at both protein level (top down or middle down proteomics) and peptide level (part of bottom up proteomics) [3,4,6,10,36]. For example, phosphoproteomics consists at identification of the phosphorylation sites at the Serine, Threonine and Tyrosine residues and their subsequent characterization and quantification [3,4,6]. The most common approaches used for identification of these phosphorylation sites are enrichment at the protein level (anti-phosphotyrosine antibodies and less popular anti-phosphothreonine/serine antibodies) or peptide level (metal-based affinity purification such as TiO2, affinity chromatography, immobilized metal affinity chromatography (IMAC), or a combination of both [4,7,8,15]. There are also similar approaches for other protein PTMs such as lectins for glycoproteins or glycopeptides, anti-nitrotyrosine for enrichment of nitrotyrosine residues or anti-acetyl-lysine antibodies for enrichment of the acetylated lysine residues. At the mass spectrometry level, methods like multiple reaction monitoring, information dependent data analysis (data-dependent analysis using an inclusion list) or neutral loss are common methods for identification of protein PTMs [4-8,14,15,17,22,28].

Challenges

As previously briefly described, there are many options for identification, characterization and quantification of protein PTMs [4-8,14,15,17,22,28]. The challenge is not so much in the biochemical and proteomic characterization of the stable or common protein PTMs such as phosphorylation or acetylation but rather for the transient or uncommon protein PTMs. For example, there are challenges in identification of transient phosphorylations (e.g. during signal transduction pathways) or in identification of PTMs such as nitrosylation, farnesylation, glycosylation or identification of disulfide bridges [4-8,14,15,17,22,28]. In addition, while there are established methods for identification of disulfide bridges and determination of O-and N-linked glycosylation sites and the structure of the glycan structure, it is not possible to automate these methods [4-8,14,15,17,22,28]. Furthermore, for the methods that can be automated (e.g. phosphorylation of acetylation), prior enrichment is necessary [6-8,15].

For basic research, one wonders about considering PPIs as possible PTMs. While ubiquitynlation is considered a PTM, it is in fact a covalent PPI. Therefore, functional PPIs can also be considered PTMs. The challenge in PPI PTMs is to accurately identify them and most difficult to validate them. Having these PPIs in mind, one also wonders whether conformation of one protein is also a non-covalent PTM, which can in fact lead to two different protein configurations. A very good example is the existence of identical antibodies with similar conformations, but with different configurations (different disulfide linkage) [37].

For the biotechnology and pharmaceutical companies, protein and/or antibody characterization (with or without conjugation with a cytotoxic or cytostatic drug) is the biggest challenge, since the disulfide
bridges in these proteins may not be identical in different protein batches or the glycosylation may not happen or may even happen at different sites. An example of such a surprise was recently published by Sokolowska and colleagues [28], where they demonstrated that introduction of new glycosylation sites in a protein may in fact change its conformation and the location of the glycan group.

Another challenge lies in the significance of a PTM. What does actually a PTM in a protein mean for a 1) protein and 2) a cellular process at a particular time point. If for a protein, a PTM mostly means change of stability, conformation, function, or a combination of all of them, for a cellular process, it is more difficult to define a PTM. In the classical example of the phosphorylation at different sites of the Protein Kinase A (PKA), described in the Biochemistry textbook [38], different degrees of phosphorylation of PKA means different degrees of enzymatic activity. However, in the mass spectrometry field (especially in phosphoproteomics), many research groups report a fold-ratio in the phosphorylation level of the proteins from two different conditions. Does this reflect an accurate and perhaps direct relationship between the PTM level (in this case phosphorylation) of a protein and its function? Can this be applied to structural proteins, as well? If yes, how?

Other challenges that the researchers face when they study protein PTMs are the artificial (experimental)-induced PTMs. Methionine, cysteine and tryptophan easily oxidize, Serine, threonine, glutamate and aspartate easily loose water, arginine, lysine, asparagine and glutamime easily deamidate or cyclisize. In addition, other common experimentally-induced modifications such as alkylation can modify proteins at sites and amino acids previously unknown, and therefore, a peptide that contains such a modification will not be identified by a mass spectrometer [3-5,16,17,20,26,28].

**Perspectives**

The human genome has been sequenced. We have about 30,000 genes that produce, in the best case, about 100,000 protein isoforms. With the given number of genes and their protein products, we are not that complicated. However, what makes a big, a really big difference is the PTMs in proteins, whose number easily increases the number of proteins to several million isoforms, which are far from being identified and structurally and functionally characterized.

**References**

1. Darie CC (2013) Mass Spectrometry and Proteomics: Principle, Workflow, Challenges and Perspectives. Mod Chem Appl 1: e105.
2. Darie CC (2013) Investigation of protein-protein interactions by blue native-PAGE & mass spectrometry. Mod Chem Appl 1: e111.
3. Nguonou Wiete AG, Sokolowska I, Woods AG, Roy U, Deinhardt K, et al. (2013) Protein-protein interactions: switch from classical methods to proteomics and bioinformatics-based approaches. Cell Mol Life Sci.4.
4. Nguonou Wiete AG, Sokolowska I, Woods AG, Roy U, Loo JA, et al. (2013) Investigation of stable and transient protein-protein interactions: Past, present, and future. Proteomics 13: 538-557.
5. Sokolowska I, Woods AG, Wagner J, Dorler J, Wormwood K, et al. (2011) Mass spectrometry for proteomics-based investigation of oxidative stress and heat shock proteins. Oxidative Stress: Diagnostics, Prevention, and Therapy 369-411.
6. Woods AG, Sokolowska I, Yakubu R, Butkiewicz M, LaFleur M, et al. (2011) Blue native page and mass spectrometry as an approach for the investigation of stable and transient protein-protein interactions. Oxidative Stress: Diagnostics, Prevention, and Therapy 341-367.
7. Darie CC, Shetty V, Spellman DS, Zhang G, Xu C, et al. (2008) Blue Native PAGE and mass spectrometry analysis of the ephrin stimulation-dependent protein-protein interactions in NG108-EphB2 cells. NAGO Science for Peace and Security Series A: Chemistry and Biology 3-22.
8. Darie CC, Deinhardt K, Zhang G, Cardasis HS, Chao MV, et al. (2011) Identifying transient protein-protein interactions in EphB2 signaling by blue native PAGE and mass spectrometry. Proteomics 11: 4514-4528.
9. Darie CC, Janssen WG, Litscher ES, Wassarman PM (2008) Purified trout egg vitelline envelope proteins VEbeta and VEgamma polymerize into homomeric fibrils from diners in vitro. Biochim BiophysActa 1784: 385-392.
10. Aitken A (2005) Identification of post-translational modification by mass spectrometry, The Proteomics Protocols Handbook 431-437.
11. Darie CC, Biniossek ML, Winter V, Mutschler B, Haehnel W (2005) Isolation and structural characterization of the Ndh complex from mesophyli and bundle sheath chloroplasts of Zea mays. FEBS J 272: 2705-2716.
12. Darie CC, De Pascalis L, Mutschler B, Haehnel W (2006) Studies of the Ndh complex and photosystem II from mesophyll and bundle sheath chloroplasts of the C4-type plant Zea mays. J Plant Physiol 163: 800-808.
13. Darie CC, Litscher ES, Wassarman PM (2008) Structure, processing, and polymerization of rainbow trout egg vitelline envelope proteins. NATO Science for Peace and Security Series A: Chemistry and Biology 23-36.
14. Nguonou Wiete AG, Sokolowska I, Woods AG, Wormwood KL, Dao S, et al. (2013) Automated mass spectrometry-based functional assay for the routine analysis of the secretome. J Lab Autom 18: 19-29.
15. Spellman DS, Deinhardt K, Darie CC, Chao MV, Neubert TA (2008) Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteomics 7: 1067-1076.
16. Wassarman PM, Jovine L, Q H, Williams Z, Darie C (2005) Recent aspects of mammalian fertilization research. Mol Cell Endocrinol 234: 95-103.
17. Sokolowska I, Nguonou Wiete AG, Woods AG, Darie CC (2012) Characterization of the anti-HBV activity of HLP1-23, a human lactoferrin-derived peptide. J Med Virol 85: 780-788.
18. Florian PE, Macovei A, Lazar C, Milac AL, Sokolowska I (2013) Characterization of the anti-HBV activity of HLP1-23, a human lactoferrin-derived peptide. J Med Virol 85: 780-788.
19. Sokolowska I, Dorobantu C, Woods AG, Macovei A, Branza-Nichita N (2012) Proteinomic analysis of plasma membranes isolated from undifferentiated and differentiated HeLaRg cells. Proteome Sci 10: 47.
20. Thome J, Coogan AN, Woods AG, Darie CC, Hassler F (2011) CLOCK genes and circadian rhythmicity in alzheimer disease. J Aging Res 2011: 385091.
21. Darie CC, Biniossek ML, Gawanowicz MA, Milgrom Y, Thurnfart JO, et al. (2005) Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg. J Biochem 126: 37585-37598.
22. Darie CC, Biniossek ML, Jovine L, Litscher ES, Wassarman PM (2004) Structural characterization of fish egg vitelline envelope proteins by mass spectrometry. Biochemistry 43: 7459-7478.
23. Nguonou Wiete AG, Sokolowska I, Wormwood K, Michel TM, Thome J, et al. (2013) Mass spectrometry for the detection of potential psychiatric biomarkers. Journal of Molecular Psychiatry 1: 1-8.
24. Roy U, Sokolowska I, Woods AG, Darie CC (2012) Structural investigation of tumor differentiation factor. Biotechnol Appl Biochem 59: 445-450.
25. Sokolowska I, Gawanowicz MA, Nguonou Wiete AG, Darie CC (2012) Disulfide proteomics for identification of extracellular or secreted proteins. Electrophoresis 33: 2627-2636.
26. Woods AG, NguonouWiete AG, Sokolowska I, Russell S, Ryan JP, et al. (2013) Mass spectrometry as a tool for studying autism spectrum disorder. J Mol Psychiatry 1: 1-6.
27. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, et al. (2012) Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 16: 1184-1195.
28. Sokolowska I, NguonouWiete AG, Roy U, Woods AG,Darie CC (2013) Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins. Biochim BiophysActa 1834: 1474-1483.
29. Woods AG, Sokolowska I, Darie CC (2012) Identification of consistent alkylation of cysteine-less peptides in a proteomics experiment. Biochem Biophys Res Commun 419: 305-308.

30. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R). Cell Mol Life Sci.

31. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of a potential tumor differentiation factor receptor candidate in prostate cancer cells. FEBS J 279: 2579-2594.

32. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells. J Biol Chem 287: 1719-1733.

33. Woods AG, Sokolowska I, Deinhardt K, Sandu C, Darie CC (2013) Identification of tumor differentiation factor (TDF) in select CNS neurons. Brain Struct Funct.

34. Aebersold R, Goodlett DR (2001) Mass spectrometry in proteomics. Chem Rev 101: 269-295.

35. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422: 198-207.

36. Loo JA, Yan W, Ramachandran P, Wong DT (2010) Comparative human salivary and plasma proteomes. J Dent Res 89: 1016-1023.

37. Jones LM, Zhang H, Cui W, Kumar S, Sperry JB, et al. (2013) Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks. J Am Soc Mass Spectrom 24: 835-845.

38. Lehninger A, Nelson DA, Cox MM (2008) Lehninger Principle of Biochemistry. W.H. Freeman.